American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016

Camacho, Pauline M.; Petak, Steven M.; Binkley, Neil; Clarke, B.L.; Harris, Steven T.; Hurley, Daniel L.; Kleerekoper, Michael; Lewiecki, E. Michael; Miller, Paul D.; Narula, Harmeet Singh; Pessah-Pollack, Rachel; Tangpricha, Vin; Wimalawansa, Sunil J.; Watts, Nelson B.

doi:10.4158/ep161435.gl

Cited by 446 publications

(486 citation statements)

References 289 publications

Supporting

Mentioning

430

Contrasting

Unclassified

Order By: Relevance

“…(1)(2)(3) In the setting of this uncertainty, the timely article by Cummings and colleagues in the current issue of JBMR, in which they present a post hoc analysis of their randomized placebocontrolled FREEDOM Trial, should have an immediate clinical impact. (4) In this report, Cummings and colleagues compare the rates of new or worsening vertebral fractures in postmenopausal osteoporotic women who discontinued denosumab with those who discontinued placebo.…”

mentioning

confidence: 99%

An Essential Warning

Leder

2017

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

mentioning

confidence: 99%

An Essential Warning

Leder

2017

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

“…Even in glucorticoid-induced osteoporosis, for which a study [35] showed fewer fractures in patients treated with teriparatide than with alendronate, the American College of Rheumatology still recommends oral bisphosphonates. Despite this, a case Endocrinologists [36]. Increasing bone mass and improving microarchitecture with an anabolic drug before starting a bisphosphonate might change the risk for fracture when the patient is assessed after 5 years of anti-resorptive therapy.…”

Section: Avoiding Aff By Optimization Of Long Term Osteoporosis Managmentioning

confidence: 99%

MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy

Adler

2018

European Journal of Endocrinology

View full text Add to dashboard Cite

Modern osteoporosis treatment began in the mid-1990's with the approval of aminobisphosphonates, anti-resorptive agents that have been shown to decrease osteoporotic fracture risk by about half. In 2005, the first cases of atypical femoral fractures (AFF), occurring in the shaft of the femur, were reported. Since then, more cases have been found, leading to great concern among patients and a dramatic decrease in bisphosphonate prescribing. The pathogenesis and incidence of AFF are reviewed herein. Management and an approach to prevention or early detection of AFF are also provided. Denosumab, a more recently approved anti-resorptive medication has also been associated with AFF. Long term management of osteoporosis and prevention of fracture are challenging in light of this serious but uncommon side effect, yet with an aging population osteoporotic fracture is destined to increase in frequency.

show abstract

“…Consequently, various groups have recommended limiting the use of HRT in postmenopausal women at risk of facture and women younger than 60 years or within 10 years of menopause (19). Alternatives to estrogen for the treatment of postmenopausal osteoporosis as recommended by the U.S. Food and Drug Administration (FDA) include bisphosphonates, raloxifene, calcitonin and denosumab; however, these drugs have been reported to exert drug-specific adverse effects (20). In turn, lifestyle modifications have been undertaken, such as changes in exercise and diet.…”

Section: Introductionmentioning

confidence: 99%

Effect of anthocyanin-rich bilberry extract on bone metabolism in ovariectomized rats

et al. 2017

View full text Add to dashboard Cite

Abstract. Menopause is associated with increased oxidative stress, which serves a role, in part, in the pathogenesis of postmenopausal bone loss. Fruits and vegetables are rich in antioxidative nutrients and phytochemicals. Berries are a natural source of anthocyanins, and their intake may improve bone health. The aim of the present study was to determine the effect of an anthocyanin-rich bilberry extract (VME) on bone metabolism in an ovariectomized (Ovx) rat. Female Sprague-Dawley rats (12 weeks old) were randomly divided into the following four groups: Baseline, Sham, Ovx and Ovx+VME (n=8-12 rats per group). Rats in the Baseline group were sacrificed immediately, while those in the other groups were subjected to either sham operation (Sham) or bilateral Ovx (Ovx and Ovx+VME). Rats in the Ovx+VME group were administered VME daily at a dose of 500 mg/kg body weight. At 8 weeks after surgery, bone mass and bone histomorphometry were evaluated. The femur bone mineral density (BMD) in the Ovx group was significantly lower than that in the Sham group (P<0.01). Supplementation of VME in the Ovx rats did not result in an increase in BMD. Histomorphometric analyses revealed that Ovx resulted in decreased measures of bone volume and trabecular number and increased measures of osteoid volume, mineralizing surface and bone formation rates (all P<0.01), whereas VME had no significant effects on these parameters. The present findings indicate that VME did not alter bone metabolism in Ovx rats, suggesting that consumption of VME may not be helpful in preventing postmenopausal bone loss.

show abstract

American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016

Abstract: A complete list of the Reviewers of the AACE/ACE Postmenopausal Osteoporosis Clinical Practice Guidelines can be found in the Acknowledgment. The American Association of Clinical Endocrinologists/American College of Endocrinology Medical Guidelines

Cited by 446 publications

References 289 publications

An Essential Warning

An Essential Warning

MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy

Effect of anthocyanin-rich bilberry extract on bone metabolism in ovariectomized rats

Contact Info

Product

Resources

About